Basel, Switzerland – Lonza, one of the world’s largest healthcare manufacturing organizations, said Tuesday it appointed Wolfgang Wienand as new CEO, succeeding Albert M. Baehny in 2024.
Wienand, currently CEO of Siegfried Holding AG, brings CDMO industry experience. Baehny will retire after a transition period. Lonza operates across divisions like Biologics and Small Molecules.
Lonza Acquires Genentech Biologics Manufacturing Site in Vacaville
Merck Invests €300 million in new Bioprocessing Center in South Korea
Update: Heidelberg Materials Ups Dividend, Extends Mandate von Achten as Chairman